Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study
Annick Moens, Marc Ferrante(Universitair Ziekenhuis Leuven), Wouter Van Moerkercke, Stéphane Nancey, Ariella Bar‐Gil Shitrit, Anneleen Van Hootegem, Séverine Vermeire(KU Leuven), Jochen Nijs(Tenneco (Belgium)), Peter Bossuyt(Imelda Hospital), Frank Hoentjen(Radboud University Nijmegen), Anneline Cremer, Daniel C. Baumgart(Humboldt-Universität zu Berlin), Evelien Humblet, Jean‐François Rahier(UCLouvain), Édouard Louis(Centre Hospitalier Universitaire de Liège), Carl Eriksson, A Posen, Zoran Milenković, C. Janneke van der Woude(Erasmus University Rotterdam), Juliette Sheridan, C. Gilletta de Saint-Joseph, Thomas Krause, S Dewit, Elisabeth Macken(Province of Antwerp), Mette Julsgaard
Cited by 137
Related Papers
Crohn's disease
|The Lancet|2012|2.1k
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
|Nature Genetics|2011|1.4k
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
|The Lancet|2015|776
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry
|Gastroenterology|2020|692
Evaluation of diagnostic tests when there is no gold standard. A review of methods
|Health Technology Assessment|2007|526